We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF). Fifty-eight subjects had ≥1 non-driver mutation upon diagnosis. Mutations in mRNA splicing genes, especially in U2AF1, were significantly more frequent in PMF than in post-PV/ET MF (33 vs. 6%; P = 0.015). There were also striking differences in clonal architecture. These data indicate different genomic spectrums between PMF and post-PV/ET MF.
CITATION STYLE
Li, B., Gale, R. P., Xu, Z., Qin, T., Song, Z., Zhang, P., … Xiao, Z. (2017, May 2). Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-017-0472-5
Mendeley helps you to discover research relevant for your work.